

Intellectual Property Strengthened Around Lead Clinical Drug HER-Vaxx

- **HER-Vaxx patent life extended to 2036**
- **Core patent provides method of composition and method of use protection**
- **Up to six additional years of peak sales**

February 27, 2017: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, today announced it has received a Notice of Acceptance from the Australian Patent Office for Patent Application 2016250289 titled “A vaccine composition and uses thereof”, which protects its HER-Vaxx cancer immunotherapy, currently in development for gastric cancer.

This new patent protects innovative new vaccine formulations designed to enhance the immune response obtained on administration of HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response in patients with HER-2 positive cancers. As recently published in the journal BMC Cancer, and announced 13 Feb 17, the enhanced formulation of HER-Vaxx incorporates an existing, clinically and commercially validated vaccine carrier protein called CRM197 together with an adjuvant.

“The strengthening of our patent portfolio is an important milestone and underpins our commercialisation strategy,” said Ms. Leslie Chong, Chief Executive Officer of Imugene.

“This new patent protects HER-Vaxx until 2036 which is significantly longer than the vast majority of competing clinical stage products and technologies. The additional patent life adds an additional six years to the time HER-Vaxx could remain generating peak sales, adding to the total amount of potential sales achievable by HER-Vaxx and hence significantly increasing the value of HER-Vaxx” Ms. Chong added.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1 million new cases diagnosed each year.

For further information please contact:

Leslie Chong
Chief Executive Officer

T: +61 458 040 433

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

In December 2016, Imugene announced an exclusive agreement with the internationally respected Baker IDI Heart & Diabetes Institute in Melbourne to research, develop and commercialise a portfolio of small molecule arginine modulators for oncology.